| Date Filed | Type | Description |
| 10/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/13/2023 |
8-K
| Quarterly results |
| 09/29/2023 |
8-K
| Other Events Interactive Data |
| 08/25/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 08/25/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/24/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/23/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/17/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/14/2023 |
4
| Lask Alisa (Director) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 12,000 shares
@ $0.49, valued at
$5.9k
|
|
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/02/2023 |
8-K
| Resignation/termination of a director |
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/11/2023 |
4
| COWAN GREGORY L (Director) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Granted 40,000 shares
@ $0 |
|
| 07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 06/02/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/22/2023 |
4
| Schaub James (EVP and COO) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 5,577 shares
@ $0.87, valued at
$4.9k
|
|
| 05/22/2023 |
4
| Klein Christopher (General Counsel & Secretary) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Paid exercise price by delivering 5,447 shares
@ $0.87, valued at
$4.7k
|
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/24/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/20/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/20/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/07/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/30/2023 |
4
| Burgstahler David F (10% Owner) has filed a Form 4 on RVL Pharmaceuticals plc|
Txns:
| Disposed of 1,032,995 shares
@ $0 |
|
|